A Nektar Therapeutics Inc. treatment aimed at ovarian cancer has been designated an orphan drug by the Food and Drug Administration.
This means the drug, aimed at a disease that fewer than 200,000 people in the country get each year, will have seven years of market protection. Nektar (NASDAQ: NKTR) will also get tax credits related to the drug.
No comments:
Post a Comment